Evidence map›Paper›PMID 38273788›Full record

ReviewDiabetes & metabolism journal2024

Risk Prediction and Management of Chronic Kidney Disease in People Living with Type 2 Diabetes Mellitus.

Ying-Guat Ooi, Tharsini Sarvanandan, Nicholas Ken Yoong Hee, Quan-Hziung Lim, Sharmila S Paramasivam, Jeyakantha Ratnasingam, Shireene R Vethakkan, Soo-Kun Lim, Lee-Ling Lim

Open access · goldAbstract readReview
In one paragraph

Review in Diabetes & metabolism journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 3 countries.

Ying-Guat OoiDepartment of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Tharsini SarvanandanDepartment of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Nicholas Ken Yoong HeeDepartment of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Quan-Hziung LimDepartment of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Sharmila S ParamasivamDepartment of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Jeyakantha RatnasingamDepartment of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Shireene R VethakkanDepartment of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Soo-Kun LimDepartment of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Lee-Ling LimDepartment of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
University of Malaya · MYChinese University of Hong Kong · HK

Funding

University of Malaya ST048-2023
6 · The paper itself

Abstract

People with type 2 diabetes mellitus have increased risk of chronic kidney disease and atherosclerotic cardiovascular disease. Improved care delivery and implementation of guideline-directed medical therapy have contributed to the declining incidence of atherosclerotic cardiovascular disease in high-income countries. By contrast, the global incidence of chronic kidney disease and associated mortality is either plateaued or increased, leading to escalating direct and indirect medical costs. Given limited resources, better risk stratification approaches to identify people at risk of rapid progression to end-stage kidney disease can reduce therapeutic inertia, facilitate timely interventions and identify the need for early nephrologist referral. Among people with chronic kidney disease G3a and beyond, the kidney failure risk equations (KFRE) have been externally validated and outperformed other risk prediction models. The KFRE can also guide the timing of preparation for kidney replacement therapy with improved healthcare resources planning and may prevent multiple complications and premature mortality among people with chronic kidney disease with and without type 2 diabetes mellitus. The present review summarizes the evidence of KFRE to date and call for future research to validate and evaluate its impact on cardiovascular and mortality outcomes, as well as healthcare resource utilization in multiethnic populations and different healthcare settings.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2Kidney Failure, ChronicRenal Insufficiency, ChronicHumansAlbuminuriaDiabetes mellitusGlomerular filtration rateKidney failure, chronicRenal insufficiency, chronicRisk assessment

Identifiers

PMID38273788
PMCPMC10995482
OpenAlexW4391262111

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.